Equities analysts predict that Portola Pharmaceuticals Inc (NASDAQ:PTLA) will report $10.43 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Portola Pharmaceuticals’ earnings. The highest sales estimate is $10.69 million and the lowest is $10.16 million. Portola Pharmaceuticals posted sales of $9.80 million during the same quarter last year, which suggests a positive year-over-year growth rate of 6.4%. The business is expected to announce its next quarterly earnings report on Wednesday, February 27th.

On average, analysts expect that Portola Pharmaceuticals will report full year sales of $35.41 million for the current fiscal year, with estimates ranging from $34.99 million to $35.73 million. For the next year, analysts expect that the company will post sales of $97.16 million, with estimates ranging from $61.31 million to $138.41 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Portola Pharmaceuticals.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.46. The business had revenue of $14.20 million during the quarter, compared to the consensus estimate of $7.10 million. Portola Pharmaceuticals had a negative net margin of 1,020.52% and a negative return on equity of 135.08%. The company’s revenue for the quarter was up 270.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.41) EPS.

Several analysts have recently commented on PTLA shares. Oppenheimer set a $60.00 price objective on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, August 26th. MED reduced their price objective on shares of Portola Pharmaceuticals from $70.00 to $60.00 and set a “positive” rating for the company in a research report on Monday, August 27th. Zacks Investment Research raised shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Wednesday. BidaskClub downgraded shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th. Finally, William Blair reaffirmed a “buy” rating on shares of Portola Pharmaceuticals in a research report on Wednesday, September 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. Portola Pharmaceuticals has an average rating of “Buy” and a consensus price target of $42.86.

In other Portola Pharmaceuticals news, Director Jeffrey W. Bird purchased 137,563 shares of Portola Pharmaceuticals stock in a transaction that occurred on Tuesday, August 21st. The stock was acquired at an average price of $25.17 per share, with a total value of $3,462,460.71. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeffrey W. Bird purchased 390,000 shares of Portola Pharmaceuticals stock in a transaction that occurred on Thursday, August 23rd. The stock was acquired at an average cost of $25.84 per share, with a total value of $10,077,600.00. The disclosure for this purchase can be found here. Company insiders own 4.60% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James & Associates grew its position in Portola Pharmaceuticals by 102.9% in the 2nd quarter. Raymond James & Associates now owns 40,302 shares of the biopharmaceutical company’s stock valued at $1,522,000 after purchasing an additional 20,441 shares during the period. Russell Investments Group Ltd. grew its position in Portola Pharmaceuticals by 67.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 129,000 shares of the biopharmaceutical company’s stock valued at $4,872,000 after purchasing an additional 52,148 shares during the period. Harvey Capital Management Inc. grew its position in Portola Pharmaceuticals by 17.3% in the 3rd quarter. Harvey Capital Management Inc. now owns 184,672 shares of the biopharmaceutical company’s stock valued at $4,917,000 after purchasing an additional 27,192 shares during the period. MetLife Investment Advisors LLC grew its position in Portola Pharmaceuticals by 16.9% in the 2nd quarter. MetLife Investment Advisors LLC now owns 29,932 shares of the biopharmaceutical company’s stock valued at $1,131,000 after purchasing an additional 4,318 shares during the period. Finally, Sector Gamma AS grew its position in Portola Pharmaceuticals by 49.0% in the 2nd quarter. Sector Gamma AS now owns 200,800 shares of the biopharmaceutical company’s stock valued at $7,584,000 after purchasing an additional 66,000 shares during the period. 93.85% of the stock is owned by institutional investors and hedge funds.

NASDAQ:PTLA opened at $20.20 on Friday. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -4.20 and a beta of 2.04. The company has a debt-to-equity ratio of 1.21, a current ratio of 6.61 and a quick ratio of 6.51. Portola Pharmaceuticals has a fifty-two week low of $18.18 and a fifty-two week high of $56.70.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness.

Read More: NASDAQ

Get a free copy of the Zacks research report on Portola Pharmaceuticals (PTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.